An Evaluation of Diverse Therapeutic Interventions for Substance Use Disorders: Serotonergic Hallucinogens, Immunotherapy, and Transcranial Magnetic Stimulation by Meil, William  M. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







An Evaluation of Diverse 
Therapeutic Interventions 
for Substance Use Disorders: 
Serotonergic Hallucinogens, 
Immunotherapy, and Transcranial 
Magnetic Stimulation
William M. Meil, William Farrell and Reem Satti
Abstract
Substance Use Disorders are a substantial public health concern whose  
treatment remains challenging. High rates of relapse are in fact a hallmark of drug 
addiction despite the wide variety of psychotherapeutic and pharmacotherapeutic 
approaches. This chapter discusses three innovative and controversial therapeutic 
approaches for Substance Use Disorders that have received considerable attention: 
the use of classic serotonergic hallucinogenic drugs (LSD and psilocybin), addiction 
immunotherapy and anti-addiction vaccines, and the use of transcranial magnetic 
stimulation. These treatments are not necessarily new but are discussed because 
they represent a diverse set of approaches that address varied aspects of drug addic-
tion. Furthermore, they have an accumulated body of research from which to assess 
their future viability. For each of these therapeutic approaches this chapter consid-
ers the theoretical basis for use, history, status of the literature supporting their use, 
limitations, and potential applications. While these three interventions represent 
highly varied approaches to the treatment of Substance Use Disorders, this diversity 
may be necessary given the complex nature of addictive disorders.
Keywords: Pharmacotherapy, hallucinogens, addiction vaccines, addiction 
immunotherapy, transcranial magnetic stimulation
1. Introduction
Substance Use Disorders (SUDs) are likely to be chronic conditions for many 
effected individuals [1, 2] and are associated with a variety of negative physi-
cal and psychological health outcomes [3, 4]. Among those treated for drug and 
alcohol dependence, 40–60% relapse within a year of treatment cessation [5, 6]. 
Longitudinal cohort studies have demonstrated significant relapse rates across a 
variety of substances and yielded insight into predictors of remission and relapse. 
A recent meta-analysis of 21 long-term remission studies, conducted between 2000 
and 2015, examined follow-up periods with a minimum of three years or reported 
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lifetime remission. The results showed 35–54% achieved remission after a mean 
follow-up of 17 years. Moreover, the pooled estimated annual remission rates sug-
gested yearly remission was uncommon ranging between 6.8% and 9.1% [2]. The 
conclusion that SUDs are likely to be long-term in nature is consistent with studies 
likening them to other chronic diseases and highlights the need for treatment to 
address the chronicity of SUDs [5].
Despite the poor long-term prognosis of SUDs, research suggest treatment is 
often efficacious in the short-term [7] as well as able to positively affect the long-
term outcomes [7, 8]. Multiple longitudinal cohort studies support the efficacy of 
a variety of therapeutic approaches while at the same time revealing significant 
heterogeneity of treatment responsivity. For example, individuals treated for 
Alcohol Use Disorders (AUDs) via Alcoholics Anonymous (AA), formal treat-
ment, or a combination of the two are more likely to be abstinent after 8 years than 
untreated individuals, however the AA only group surpassed the formal treatment 
group at 1- and 3-year follow-ups [9]. Another study of adults with AUD, most of 
whom were entering treatment, revealed five trajectory classes distinguished by 
their changes in drinking patterns across three years with AA involvement predict-
ing abstinence and/or declines in drinking over time [10]. A recent prospective 
longitudinal cohort study examining heroin use and treatment utilization over 
10–11 years also identified five trajectory groups related to treatment utilization 
and continued drug use [8].
Addiction is fundamentally a brain disease in which chronic use of substances 
produce neuroplastic changes across multiple brain systems rendering a person 
more vulnerable to drug craving, escalating use, and relapse. Depending on the 
effected system, these changes yield increased incentive salience towards the drug 
and drug associated cues, attenuated reward, motivation, emotion, and altered 
stress responsivity. These changes are also coupled with deficits in the prefrontal 
Figure 1. 
Therapeutic interventions under development and their putative mechanisms of action (second row from top) 
and posited anti-additive effects (third row from the top).
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cortex and related circuitry leaving drug addicted individuals with diminished 
executive function and enhanced impulsivity. Moreover, the extent to which these 
neural adaptions change over time appears to vary, but many have been shown to 
be highly durable. These neural changes must also be considered within the context 
of an individual’s genetic and epigenetic vulnerabilities, and life circumstances 
[11–13]. The complexity of variables which contribute to the development of SUDs 
make them particularly challenging to understand and treat, but they also offer a 
bevy of targets to develop new treatment approaches.
The purpose of this chapter is to examine three putative treatments for SUDs: 
serotonergic hallucinogens, immunotherapy approaches, and transcranial magnetic 
stimulation [TMS]. These treatments are not necessarily new but were chosen 
because they represent a diverse set of approaches that address varied aspects 
of drug addiction (see Figure 1). Moreover, they have an accumulated body of 
research from which to assess their future viability. For each of these therapeutic 
approaches this chapter will address the theoretical basis for use, history, status of 
the literature supporting their use, limitations, and potential applications.
2. Serotonergic hallucinogens and substance use disorders
Hallucinogenic drugs represent a diverse set of naturally occurring and synthetic 
substances which vary based on their pharmacological actions and psychoactive 
effects. The term hallucinogen typically refers to a drug that produces perceptions 
in the absence of sensory stimuli. However, it is now recognized that hallucinogens 
produce a broader range of effects across cognition and mood and that hallucina-
tions themselves are less common than the perceptual illusions and sensory distor-
tions they produce. For this reason, the term psychedelic, or mind manifesting, 
is often used to describe this class of drugs [14, 15]. This section of the chapter 
focusses on lysergic acid diethylamide (LSD) and psilocybin, two hallucinogens 
typically referred to as classic serotonergic hallucinogens because they act primarily 
as agonists on the serotonin (5-HT) 2A receptor and share behavioral effects and 
proposed therapeutic mechanisms [14].
Psilocybin occurs naturally in more than 200 species of mushrooms and has 
long been consumed by indigenous cultures to engage with the spiritual world 
[16, 17]. Albert Hofmann isolated psilocybin and its active metabolite psilocin and 
subsequently synthesized them in 1958 [18]. LSD was first synthesized in 1938 by 
Hofmann from ergotamine, a compound found in ergot fungus. After preclinical 
administration failed to reveal many observable effects in laboratory animals its 
psychoactive properties were recognized following an accidental ingestion of the 
drug by Hofmann in 1943. Beginning in the mid-1950s LSD and psilocybin were 
widely distributed under the names Delysid and Indocybin for study of multiple 
psychological disorders resulting in more than 1000 papers, treating more than over 
40,000 individuals by the mid-to-late 1960’s [16, 18–20].
The main focus of research through the late 1960s on the efficacy of hallucino-
gens in the treatment of addiction was the ability of LSD to attenuate alcoholism 
[21]. Among the first studies was that of Hoffer & Osmond [22] who followed 24 
treatment resistant alcoholics. After taking several weeks to establish a psycho-
therapeutic relationship, participants were administered a single dose of 200–400 
micrograms of LSD while accompanied by a nurse and/or a psychiatrist and in 
many cases, efforts were made to create a therapeutic environment. The next day, 
participants were asked to write about their experience. Six participants were 
considered much improved (complete abstinence and positive lifestyle changes) 
and another six improved at the conclusion of the study [22].
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This early research was influential in establishing a treatment model referred to 
as “psychedelic therapy” [22], though over time the nature of treatment sessions 
has varied greatly [21, 23]. Central to this therapeutic approach is the idea that 
patients will experience a psychedelic peak characterized by an ecstatic state, visual 
hallucinations, a loss of boundaries between the individual and the objective world, 
feelings of unity with others, nature, God and the universe [19, 21]. The result of 
this peak being the induction of a mystical experience that would profoundly alter 
the way a person views themselves and the world [20]. The dramatic nature of this 
experience is then interpreted with the assistance of a trained therapist who helps 
the patient appreciate the psychotherapeutic benefits of the experience [24].
In the following years more than 20 studies with larger sample sizes were 
published illustrating the effectiveness of LSD for treating alcoholism with many 
describing unprecedented levels of success [19, 25]. From, 1954–1960 Osmond 
and colleagues studied the effects of LSD on approximately 2000 alcoholics find-
ing almost half were abstinent after a year [26]. However, by and large this body 
of research suffered from significant methodological flaws among them a lack of 
diagnostic specificity, non-random assignment of participants, lack of control and 
or placebo groups, inconsistent participant follow-up, participant attrition, absence 
of blind raters, and a lack of clarity in assessing treatment efficacy. Despite these 
flaws, these early findings were encouraging enough that by the late 1960s six alco-
holism treatment programs in North America used LSD based therapy [19, 23, 25].
Gradually some of the methodological problems that plagued earlier studies 
were partially addressed and a meta-analysis was conducted of six randomized 
controlled studies (five of which were double-blind) between 1966 and 1970 
examining the efficacy of LSD in the treatment of alcoholism [27]. Across these 
studies 536 adults suffering from alcoholism were compared to 211 control partici-
pants receiving a low-dose LSD, d-amphetamine, ephedrine sulphate or non-drug 
control. While the characteristics of LSD sessions and follow up varied consider-
ably, the results supported the efficacy of a single dose of LSD. Decreases in alcohol 
misuse were observed at 2–3 and 6 months, but not 12 months post-treatment. 
Moreover, in three studies reporting total abstinence from alcohol, LSD showed 
benefits 1–3 months after discharge from treatment programs. Despite these results, 
research examining the utilization of LSD for alcoholism stalled by the late 1960s 
due to increased recreational use, its association with the drug counterculture 
movement, increased restrictions on human drug research, continued method-
ological concerns, ambiguous results, and passage of the Controlled Substances Act 
of 1970, which placed LSD in the most restrictive category of drugs [15, 18, 25, 28].
After a cessation of almost 30 years, controlled studies in humans using 
hallucinogens resumed in the late 1990s [18, 24]. However, Psilocybin, not LSD, 
emerged as the drug of choice to study the effects of hallucinogens on SUDs  
[18, 23, 24]. Multiple reasons have been put forward for psilocybin’s emergence 
in this context. Psilocybin has a shorter duration of action compared to LSD, and 
psilocybin is believed to have a milder side effect profile producing less anxiety, 
affective disturbances, and milder vegetative side effects [16, 28]. Also, LSD may 
still suffer from its negative counterculture reputation of the 1960s and a litany 
of mass media misinformation including exaggerated claims of drug-induced 
insanity, chromosomal damage, and other falsehoods [14, 15]. In contrast there is 
growing interest in certain locales to legalize psilocybin’s use in licensed facilities 
for mental health purposes and decriminalize it in others [29].
Among the limited number of recent studies is a small open-label trial with 
psilocybin for AUD [30]. Psilocybin was administered to 10 alcohol dependent 
individuals in context of a 12-week program of motivational enhancement therapy. 
Participants were initially administered 0.3 mg/kg of oral psilocybin followed by 
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a second dose of 0.3 or 0.4 mg/kg, 4 weeks later. The two doses of psilocybin were 
separated by four therapy sessions and the final dose was followed by another 
four sessions. Following the initial psilocybin treatment self-reported alcohol use 
significantly decreased and remained below baseline at a 36-week follow-up. In 
addition, significant correlations were reported between the overall intensity and 
mystical quality of psilocybin sessions and reductions in the percent of drinking 
days, alcohol craving, and self-efficacy to abstain.
Research examining psilocybin’s ability to treat nicotine addiction is also prom-
ising. An open-label study was conducted with 15 treatment-resistant, nicotine 
dependent participants administered 2–3 moderate and high doses of oral psilo-
cybin integrated within a 15-week cognitive behavioral therapy program. Using 
biologically based verification procedures at a 6-month follow-up 80% of partici-
pants were abstinent, at 12 months 67% remained nicotine free, and at 16 months 
60% were abstinent. After a long-term follow-up averaging 2.5 years, 75% of study 
participants were verified as nicotine free. Moreover, participants abstinent at 
6-months scored higher on measures of mystical experiences following psilocybin 
compared to those who relapsed. Greater mystical-type experiences following psilo-
cybin administration also correlated with reduced nicotine cravings at 6 months. At 
the 12-month follow-up participants rated their psilocybin experience among the 5 
most personally meaningful and spiritually significant of their lives [31, 32].
A variety of additional factors speak to the potential viability of serotonergic 
hallucinogens for the treatment of SUDs. A single or a limited number of drug 
administrations during supervised treatment sessions may negate a number of 
liabilities associated with other pharmacotherapies such as high cost, problems with 
medication adherence, drug interactions and side effects [24]. LSD and psilocybin 
have a limited addictive liability as indicated by a lack of drug self-administration 
by laboratory animals [28, 33], relatively slow onset of effects after oral administra-
tion not typically characterized by pleasure or craving and has no direct effects on 
the brain dopamine pathways [15]. Physical withdrawal symptoms do not develop 
even following prolonged use of LSD and psilocybin and the rapid development of 
dramatic tolerance, on the order of days, does not facilitate the acquisition of addic-
tive behavior [14, 33]. Methodological details associated with the use of psilocybin 
for treatment of SUDs can be found in several sources [21, 31, 33].
The general public’s perception that psychedelic drugs are dangerous, con-
tradicts the fact that from a physiological perspective they are among the safest 
classes of drugs [15]. Both drugs are not without their liabilities [14, 15, 28, 33], 
yet substantial toxicity has only been associated with a small number of users [28] 
In the context of clinical use, the incidence of problems is substantially mitigated 
as patients are typically prescreened for psychotic symptoms and cardiovascular 
issues, receive a single or a small number of doses, pharmacotherapies may be 
available to reverse untoward effects, and therapeutic sessions are supervised by 
a trained clinician [24, 34]. Recent trials examining the efficacy of these halluci-
nogens for SUDs have reported no serious adverse effects [30–34] nor have trials 
examining these hallucinogens in patients with anxiety, depression, or healthy 
volunteers [18].
A variety of mechanisms have been suggested to explain the therapeutic efficacy 
of LSD and psilocybin for SUDs and many overlap with proposed explanations 
for addressing other psychological disorders [18, 34]. Depression and anxiety are 
hallmarks of addiction [17]. Both negative affective states have been shown to 
be ameliorated following LSD and psilocybin administration [18, 19, 34] and are 
linked to prolonged increases in optimism and wellbeing [17]. While it cannot be 
ruled out that these drug’s effects on mood and anxiety are part of a broader mecha-
nism, the fact that antidepressants [35] and anxiolytics [36] alone are generally not 
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effective treatments for managing SUDs suggest this represents at best an incom-
plete explanation for hallucinogens therapeutic effects for SUDs.
It has been widely suggested that LSD and psilocybin’s experiential effects 
underly their benefits for treating SUDS [17]. Alcoholics Anonymous has long 
argued that addiction follows from deficits in spirituality and meaning [37]. Bill 
Wilson one of the co-founders of Alcoholics Anonymous, credited his experiences 
with hallucinogens as the reason for his own abstinence and advocated for LSD as 
a pathway to sobriety [38]. Spirituality has been demonstrated to play a role in the 
success of Alcoholics Anonymous [39] and other therapeutic approaches [40] and 
a sense of purpose in life decreases chronic heavy drinking [10]. The benefits of 
hallucinogenic-based therapeutic experiences may also lie in their intensity [17] as 
their effects are often described as life changing in nature [31, 32] and research has 
shown users who experience the most profound mystical experiences consistently 
undergo the greatest symptom relief [15]. Moreover, stronger mystical experiences 
and greater intensity of subjective effects of psilocybin are associated with alcohol 
and nicotine abstinence suggesting a mediating role of mystical experience in 
psychedelic-facilitated addiction treatment [30, 41].
Consistent with the importance of hallucinogen induced experiential effects 
recent research using brain imaging in healthy volunteers has shown LSD and 
psilocybin decrease functional connectivity in the default mode network (DMN), 
a pathway bilaterally spanning the medial and lateral parietal, medial prefrontal, 
and medial and lateral temporal cortices, and whose activity appears augmented 
in depressed patients [24, 42, 43]. Moreover, administration of both drugs was 
associated with “ego-dissolution” and “altered meaning” suggesting the importance 
of this circuit for the maintenance of “self” or “ego” and its processing of “mean-
ing” [43, 44]. These results and those of other studies support the idea that classic 
hallucinogens may function to increase processing of positive stimuli and decrease 
processing of negative stimuli, elevate mood, and decrease coupling of neural net-
works allowing for unrestrained exploration of spirituality and meaning [21, 24]. 
Imaging studies of this network in those with SUD following administration of 
hallucinogens and after periods of abstinence are needed.
It is noteworthy that past and present research examining the efficacy of LSD 
and psilocybin in combination with psychotherapy for the treatment of SUD has 
been consistently promising [18]. Their benefits compare favorably with daily 
administration of naltrexone, acamprosate, and disulfiram for the treatment of 
AUD [27] and exceed success rates of behavioral and pharmacological interventions 
for nicotine dependence [31]. In addition, this approach represents a sea change in 
the dramatic, broad, and long-lasting nature of its effects and appears relatively safe 
when administered in a clinical setting. Recently a therapeutic model specifically 
for psilocybin-assisted treatment of AUD has been proposed [21], as have a neu-
roscience based mechanistic theory of explaining psilocybin’s efficacy for treating 
SUD [28], and larger randomized studies are now being conducted on the efficacy 
of psilocybin for AUD, nicotine, and cocaine dependence [34, 45]. However, the 
above advances should be tempered with the knowledge that recent research has 
had small samples, this approach is demanding on both the patient and therapist, 
hallucinogens and hallucinogen-assisted psychotherapy have a negative reputation 
and are misunderstood by many [24, 45, 46].
3. Addiction immunotherapy: anti-addiction vaccines
The primary immunotherapies being developed for SUDs are vaccines that 
cause the generation of antibodies directed against drugs of abuse such as cocaine, 
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nicotine, and opioid analgesics. The underlying rationale is that once drugs of abuse 
are bound to antibodies, the resulting complex is too large to cross the blood–brain 
barrier. This reduces the amount of abused substance that reaches the central 
nervous system (CNS) and thereby reduces the rewarding effects of the drugs. The 
development of vaccines for drugs of abuse is complicated by the fact that the drugs 
themselves are small molecules that do not inherently elicit an immune response. To 
overcome this obstacle, drug molecules or their derivatives (haptens) are typically 
attached to an immunogenic carrier molecule and administered with adjuvants to 
stimulate the generation of antibodies directed against the drug. Vaccine candi-
dates have been developed against several drugs of abuse using variations on this 
approach [47].
Cocaine abuse represents a condition for which a vaccine could be of particular 
use since there are currently no approved pharmacotherapies to promote abstinence 
or prevent relapse. Studies in the 1990s conducted in rodents demonstrated that 
anti-cocaine vaccines could induce the generation of cocaine-specific antibodies 
and reduce cocaine levels in the brain following peripheral cocaine administration 
[48, 49]. Additionally, vaccination reduced the psychostimulant (locomotion and 
stereotopy) effects of cocaine in rats [48], and vaccination or the administration of 
monoclonal antibodies against cocaine reduced cocaine self-administration and the 
reinstatement of cocaine self-administration following extinction in rats [49, 50].
Two cocaine vaccines are currently listed on ClinicalTrials.gov. The vaccine that 
has been most studied is the TA-CD vaccine. This vaccine, which consists of suc-
cinylnorcocaine (SNC) attached to a recombinant cholera toxin B (rCTB) carrier 
administered with aluminum hydroxide adjuvant, caused the generation of cocaine-
specific antibodies in rats and reduced cocaine self-administration [51]. The results 
of a randomized, double-blind, placebo controlled, Stage I clinical trial in which 
34 former cocaine abusers in a residential treatment facility were randomized to 
receive three vaccine injections during the first two months of the study at doses of 
13, 82 or 709 mg or an equivalent number of placebo injections (n = 6) indicated 
that the vaccine was well tolerated and elicited the dose-dependent production of 
cocaine-specific antibodies which peaked after the third injection and declined over 
the remainder of the year-long study [52]. A subsequent open-label, outpatient, 
treatment study involving 18 cocaine-dependent participants indicated that partici-
pants who received a total of 2000 mg of vaccine administered in five equal injec-
tions over 12 weeks achieved higher mean peak antibody titers and reduced cocaine 
use over 12 weeks relative to participants who received a total of 400 mg of vaccine 
administered in four equal injections over 8 weeks [53]. The majority of participants 
who did use cocaine during the study reported a reduction in the euphoric effects of 
the drug. The results of a subsequent study conducted in a laboratory setting with 
participants who were actively abusing cocaine indicated that participants with 
immune responses to the TA-CD vaccine above the 50th percentile reported reduced 
positive subjective effects of smoked cocaine [54].
The results from a 24-week Phase IIb clinical trial conducted with 115 cocaine- 
and opioid-dependent participants enrolled in an outpatient methadone program 
found that participants who mounted a robust antibody response (≥43 mg/ml) 
following five vaccine injections (360 mg each) administered over the course of 
12 weeks had a higher number of cocaine free urine tests during weeks 9–16 of 
the study than participants who received placebo injections or who produced a 
smaller antibody response to the vaccine [55]. These participants were also more 
likely to exhibit a 50% reduction in cocaine use between weeks 8–20 of the study 
relative to those who mounted a less robust immune response to the vaccine. 
However, a subsequent randomized, double-blind, placebo-controlled, Phase III 
clinical trial involving 300 cocaine-dependent participants in outpatient treatment 
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programs across six sites failed to demonstrate efficacy of the TA-CD vaccine [56]. 
Participants in this study received five vaccinations (400 mg each or placebo) over 
the course of 13 weeks, and 67% of the fully vaccinated participants displayed a 
robust antibody response (≥42 mg/ml). Vaccinated participants did not, however, 
have fewer cocaine-positive urine tests than participants receiving placebo injec-
tions, and participants with a robust antibody response did not exhibit a significant 
reduction in cocaine-positive urine tests relative to participants who mounted a 
lesser immune response. Participants who generated robust immune responses 
to the vaccine were, however, more likely to complete the study than those with 
weaker immune responses.
The second cocaine vaccine undergoing clinical trials is the dAd5GNE vaccine. 
One major drawback to the TA-CD vaccine was that it did not consistently elicit high 
titers of cocaine-specific antibodies. For example, in one study [55] only 38% of the 
vaccinated participants generated antibodies at the concentration projected to be 
required for efficacy. The dAd5GNE vaccine consists of the cocaine analog, GNE 
(6-(2R,3S)-3-(benzoyloxy)-8-methyl-8-azabicyclo [3.2.1] octane-2-carboxoamido-
hexanoic acid) connected to disrupted adenovirus capsid proteins administered with 
Adjuplex (Advanced BioAdjuvants, LLC, Omaha, NB) adjuvant, and was designed 
to elicit a strong immune response from humans [57]. In rodents, this vaccine has 
been demonstrated to elicit high and persistent titers of cocaine-specific antibod-
ies, attenuate the passage of cocaine from the peripheral circulation to the brain, 
reduce cocaine self-administration on a progressive-ratio schedule, and reduce 
cocaine-induced reinstatement of cocaine self-administration following extinction 
[57, 58]. The vaccine also produced high antibody titers in Rhesus macaques, reduced 
the penetration of cocaine to the CNS [59], and reduced reacquisition of cocaine 
self-administration following extinction [60]. The dAd5GNE vaccine is currently in 
a Phase I clinical trial, but results are not yet available.
Vaccines have also been developed against nicotine with the intention of helping 
users quit and remain abstinent. Vaccines that have been or are being examined in 
clinical trials include NicVax, Nic-002 (Nic-Qb), TA-NIC, Niccine, and SEL-068. 
None of these vaccines are currently approved for the treatment of tobacco use 
disorder, but further refinement and evaluation appears to be warranted. Because 
peer reviewed data related to many of these vaccines are limited, this discussion will 
focus on NicVax and Nic-002 (Nic-Qb). NicVax (3′-AmNic-rEPA) was one of the 
earliest candidate vaccines directed against nicotine. In preclinical studies, antibod-
ies generated in response to this vaccine in rabbits and injected into rats reduced 
the passage of intravenously administered nicotine to the brain in a dose-dependent 
manner and attenuated the effects of nicotine on systolic blood pressure and loco-
motor activity [61]. Similarly, active immunization of rats elicited the production of 
nicotine-specific antibodies and also attenuated the passage of nicotine to the brain 
[61]. Active immunization also reduced nicotine self-administration in rats [62].
Single photon emission computed tomography (SPECT) data collected from 
nicotine-dependent human participants, indicates that active immunization with 
NicVax reduces the binding of nicotine to β2-nicotinic acetylcholine receptors in 
the brain [63], and the results of a study involving 68 current smokers assigned to 
receive four injections of vaccine (50, 100, or 200 mg) or placebo indicated that the 
vaccine was well tolerated and that the nicotine-specific antibodies were elicited in 
quantities believed to be sufficient for efficacy at the highest dose [64]. Participants 
receiving the highest dose of vaccine were also more likely to achieve 30 days of 
abstinence than participants receiving lower doses of the vaccine or placebo injec-
tions. The results of a subsequent Phase II clinical trial [65] in which 301 smokers 
were assigned to receive four or five doses of NicVax (200 or 400 mg/injection) or 
placebo over the course of 26 weeks indicated that participants who received five 
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400 mg doses of vaccine had higher prolonged abstinence rates through both 6 and 
12 months relative to participants receiving placebo. In addition, participants with 
the highest antibody response (top 30% across all vaccine doses) were more likely 
to achieve eight weeks of abstinence between weeks 19–26 of the study, had higher 
rates of continuous abstinence from weeks 19–52 of the study, and had higher rates 
of 7-day point prevalence abstinence at weeks 26 and 52 of the study compared to 
participants receiving placebo. Participants in the high antibody response group 
were also more likely than participants receiving placebo to exhibit prolonged 
abstinence through 6 and 12-months. Unfortunately, while two subsequent Phase 
III clinical trials with NicVax confirmed that the vaccine was safe and well toler-
ated, six injections (400 mg each) of NicVax failed to significantly alter abstinence 
rates relative to placebo [66]. An additional Phase IIb study was conducted on the 
effectiveness of NicVax in combination with varenicline and motivational inter-
viewing, however, this study too failed to establish a significant effect of NicVax on 
abstinence rates relative to participants receiving placebo [67].
Nic-002 (Nic-Qb), a vaccine consisting of a virus-like particle (VLP)-nicotine 
conjugate also showed both preclinical and clinical potential for reducing nicotine 
use. This vaccine yielded high titers of nicotine-specific antibodies in mice, rats, 
and rabbits, and vaccination of mice significantly reduced brain nicotine levels 
[68]. The report of the results from a European Phase I randomized, placebo 
controlled clinical trial in which 32 healthy human participants received two 
vaccinations separated by four weeks and 8 participants received control injec-
tions indicated that the vaccine was generally well-tolerated and produced a 
robust immune response with high affinity, nicotine-specific antibodies [68]. 
The results of a subsequent phase II study in which participants, were scheduled 
to receive five 100 mg vaccinations of Nic-002 with alum adjuvant (n = 229) over 
four months or alum alone as the placebo (n = 112) [69] indicated that, continuous 
abstinence rates from months 3 to 6 of the protocol, did not differ between the 
vaccination (30.1%) and placebo groups (26.1%), the 1/3 of participants with the 
highest antibody response had a significantly higher continuous abstinence rate 
from months 2 through 6 of the study (56.6.%) compared to participants receiving 
placebo (31.3%). Furthermore, this effect was maintained through month 12 of the 
study (41.5% vs. 21.3%). While researchers believed these results to be encourag-
ing, Novartis announced that an interim analysis of data from a subsequent Phase 
II study indicated that the vaccine failed to improve continuous abstinence rates, 
likely due to insufficient antibody titers [70], and its development appears to have 
been halted.
Developing vaccines against opioid analgesics presents some unique challenges. 
One consideration is that unlike nicotine and cocaine the metabolites of many opioid 
drugs are active and can have physiological and psychological effects of their own. A 
second consideration is that if vaccines are to be used for the treatment of opioid use 
disorder, they should not bind to and inactivate opioids that are used to assist with 
treatment for the disorder or are used to prevent overdose. Finally, vaccines directed 
against one opioid analgesic will ideally not bind to other analgesics which may be 
needed for pain management. While no opioid vaccines have been tested in clinical 
trials, several candidate vaccines have emerged from preclinical investigations with 
promising results against heroin, oxycodone and fentanyl.
One example of a vaccine that appears promising for the treatment of heroin use 
consists of a heroin-tetanus toxoid (TT) combination [71]. Following administra-
tion heroin is rapidly metabolized to 6-acetyl morphine (6 AM) and subsequently 
to morphine, and these two metabolites act via mu-opioid receptors to generate 
heroin’s antinociceptive and rewarding effects. Preclinical studies with this vaccine 
have demonstrated that it generates substantial antibody titers with high affinity for 
Addictions - Diagnosis and Treatment
10
6 AM and heroin and much lower affinity for morphine, oxycodone, and metha-
done in both mice and monkeys. Additional vaccines using haptens derived from 
morphine, have also been demonstrated to reduce the CNS-mediated behavioral 
effects of heroin [72].
Vaccines have also been developed that attenuate the behavioral and physi-
ological effects of oxycodone and/or hydrocodone in rodents [72]. One of these 
vaccines, comprised of an oxycodone-based hapten conjugated to keyhole limpet 
hemocyanin (KLH), is notable, in part, for the specificity of its action [73]. Rats 
immunized with this vaccine generated antibodies with high affinity for oxyco-
done and, to a lesser extent oxymorphone, an active metabolite of oxycodone. 
Importantly cross-reactivity with naloxone and naltrexone was 1.2% or less and 
was undetectable for methadone and buprenorphine. Vaccination also reduces 
brain oxycodone levels by as much as 51% following intravenous administration 
of 0.5 mg/kg of oxycodone and significantly reduced the antinociceptive effects 
of oxycodone as indicated by performance on the hot-plate test. Furthermore, 
vaccination significantly reduced the acquisition of oxycodone self-administration 
and the number of infusions administered indicating a reduction in reinforcing 
effects of the drug.
Given the ongoing opioid crisis, a vaccine with clinical potential has also been 
developed against fentanyl [74]. This vaccine consists of a fentanyl-based hapten 
conjugated to either KLH or GMP-grade subunit KLH (sKLH). Vaccination elicited 
an immune response containing fentanyl-specific antibodies in mice and reduced 
the antinociceptive effects of fentanyl (0.05 mg/kg, s.c.) by 60% as assessed by the 
hotplate test. In addition, this vaccine elicited an immune response from rats and 
reduced the antinociceptive effects of fentanyl (0.05 mg/kg, s.c.) by 93% without 
significantly attenuating the antinociceptive effects of heroin or oxycodone. 
Fentanyl levels in the brain were also reduced by 30% following peripheral fentanyl 
administration (0.05 mg/kg, i.v.), and vaccination attenuated fentanyl-induced 
respiratory depression. Importantly, naloxone (0.1 mg/kg, s.c.) still reversed 
fentanyl-induced antinociception and respiratory depression following vaccination, 
indicating the vaccine does not render this important, life-saving drug ineffective.
While the results of clinical trials conducted thus far with vaccines against drugs 
of abuse have failed to yield consistent results indicating effectiveness, examination 
of the results obtained from participants who mounted a robust immune response 
has been encouraging. One hope is that advances in vaccine design improve will 
immune responses from participants [75]. Providing exogenous monoclonal 
antibodies against drugs of abuse to vaccinated participants might also provide a 
means of assuring that vaccine recipients have high antibody titers. This approach 
yielded improvements in combating the behavioral effects of nicotine in rats rela-
tive to vaccine administration alone [76]. It is also possible that modifying the route 
of administration could improve the efficacy of vaccines. For example, intranasal 
vaccine administration has been demonstrated to increase mucosal antibody levels 
against nicotine which could aid in the rapid immobilization of inhaled nicotine 
[77]. Intranasal administration of a cocaine vaccine has also recently been demon-
strated to have advantages preventing cocaine-induced locomotion in mice [78].
Beyond simply attenuating the rewarding effects of drugs of abuse, vaccines may 
present additional advantages for SUD. Unlike available pharmacotherapies, the 
effects of vaccines can be long-lasting and require only periodic booster immuniza-
tions to maintain effectiveness. This may make vaccination more cost-effective than 
other treatments and preclude the need for daily adherence to drug regimens. Vaccines 
against drugs of abuse should also have a reasonably low behavioral/psychological 
side-effect profile as they do not have CNS effects of their own. Because of the lack 
of direct CNS effects, well designed vaccines should also not interfere with other 
11
An Evaluation of Diverse Therapeutic Interventions for Substance Use Disorders…
DOI: http://dx.doi.org/10.5772/intechopen.98514
pharmacotherapies for substance use and could be combined with such therapies 
to enhance effectiveness. For example, while antagonist medications may be able to 
reduce the rewarding effects of drugs of abuse, users may increase their drug use in an 
attempt to override the blockade. This could leave the individual vulnerable to danger-
ous peripheral effects of the drugs. Vaccines may aid in combating these peripheral 
effects by limiting drug availability in the periphery as well. Co-administrations of 
vaccines against multiple drugs also has potential usefulness for individuals who abuse 
a mixture of substances such as fentanyl-laced heroin. The effectiveness of one such 
vaccine mixture (heroin/fentanyl) has recently been seen in mice [79].
Despite their promise, vaccines against drugs of abuse have several limitations. 
For example, vaccinated individuals could potentially increase substance intake to 
overwhelm the antibodies generated in response to the vaccine, and evidence of 
increased substance use by at least some participants has been reported in some of 
the studies discussed above [55, 56]. Additionally, participants with insufficient 
motivation to remain abstinent could discontinue treatment. Current skepticism 
about vaccines may also reduce the attractiveness of vaccines as an SUD treat-
ment. Despite these limitations, with improvement, vaccination against drugs 
of abuse may still prove to be an efficacious tool to aid motivated individuals in 
recovery.
4. Transcranial magnetic stimulation and substance use disorders
Transcranial Magnetic Stimulation (TMS) is a noninvasive medical procedure 
involving the application of fluctuating magnetic pulses generated from a coil 
placed over the scalp that passes through the skull and into the brain generating 
electrical currents which alter neural activity by electromagnetic induction. The 
coil design can influence intensity, localization, and depth of stimulation. Multiple 
TMS pulses administered consecutively are referred to as repetitive or rTMS. Low 
frequency rTMS (LF-rTMS; ≤ 1 Hz) typically attenuates neural excitation and 
cortical excitability and higher frequency rTMS (HF-rTMS; 1–20 Hz) augments 
neural excitation, cortical excitability, and regional cerebral blood flow. Stimulation 
parameters, anatomical loci, and the current cortical activity also influence its 
facilitative or suppressive effects. rTMS results in strong moderately localized 
intracranial currents in the underlying cortex but also produces long lasting 
complex changes, neurotransmitter release, plasticity, and connectivity in distal 
neural circuitry [80–83]. The present form of TMS traces its origins to Barker and 
Colleagues who demonstrated the effects of magnetic stimulation on human motor 
cortex in 1985 [84]. The therapeutic efficacy of rTMS is currently under study for 
many psychological disorders and has U.S. Food and Drug Administration approval 
for the treatment of Major Depressive Disorder in adults [80].
The methods and mechanisms associated with rTMS-induced neuroplasticity 
and therapeutic efficacy for SUD are complex and reviewed elsewhere [80–83], 
however, the majority of studies have targeted the prefrontal cortex, more specifi-
cally the dorsolateral prefrontal cortex (DLPFC) [81–83]. This structure represents 
a desirable target not only for its accessibility but because it has been directly 
linked to neuroplastic changes associated with craving, impulsivity, and executive 
function all of which play central roles in addiction [80, 81]. Moreover, the DLPF 
is highly interconnected with other cortical and subcortical circuits associated 
with anhedonia, escalation of use, and relapse [82]. The potential of this approach 
has resulted in a significant number of studies in a relatively short period across a 
variety of addictive substances, brain loci, and employing a wide range of rTMS 
methods [81–83]. Most studies on the effects of rTMS for SUD have focused on 
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alcohol, cocaine, and nicotine and those literatures are highlighted below. Limited 
research has examined opiates, methamphetamine, and cannabis [85–87].
Multiple sham-controlled studies have been conducted to examine the efficacy 
of HF-rTMS on individuals with AUD with mixed results. One single-blind study 
examined rTMS (10 Hz) in 10 sessions to the right DLPFC and measured self-
reported cravings at baseline following treatment and after 4 weeks. Significant 
decreases in craving were reported in patients who received rTMS versus sham 
rTMS [88]. A similar double-blind study comparing 10 sessions of right versus 
left DLPFC HF-rTMS (10 Hz) stimulation following treatment in those with AUD 
showed no difference in efficacy based on the side of treatment of administration 
but a significant reduction in craving scores in those administered rTMS [89]. 
Other studies using rTMS on the DLPC have failed to show effects of alcohol 
craving in those with AUD. A single session of rTMS versus sham treatment to the 
right DLPFC did not reduce craving immediately following treatment or when 
measured at home several days later [90]. Similarly, no significant differences in 
alcohol craving were reported after 10 days between sham rTMS and HF-rTMS 
of the left DLPFC, (20 Hz) [91]. Moreover, rTMS targeting the insula in alcohol-
dependent participants in a double-blind, sham-controlled, randomized trial 
receiving 10 Hz rTMS or sham stimulation 5 days a week for 3 weeks showed no 
effects of rTMS on craving and alcohol consumption. A recent systematic review 
and meta-analysis of the effects of transcranial direct current stimulation (tDCS; 
11 studies) and rTMS (23 studies), most targeting aspects of the prefrontal cortex, 
on alcohol craving concluded there was no evidence of positive effects on alcohol 
craving [92]. However, the positive results found in some studies and the variabil-
ity in study quality and methodology underscore the need for further research in 
this area [93].
To date no medication has clearly emerged as an efficacious treatment for 
cocaine or methamphetamine addiction [81], making the positive results with 
r-TMS for psychostimulant addiction particularly noteworthy. The benefits of a 
single 10 Hz rTMS exposure over right, but not left, DLPFC was found to tran-
siently attenuate cocaine craving [94] and many studies have now illustrated the 
ability of multiple administrations to attenuate craving and use in cocaine depen-
dent individuals. Among these is a between-subject randomized study examin-
ing stimulation of the left DLPFC using HF-rTMS (15 Hz administered during 
8 sessions) versus a control group receiving a mixture of putative medications 
for cocaine addiction during a 29-day period. Results showed significantly more 
cocaine-free urine tests and lower craving scores in the rTMS treatment group 
[95]. In a study examining use, craving, and other markers indicative of cocaine 
dependence 20 individuals with cocaine use disorder (CUD) received 2 weeks of 
rTMS administration (15 Hz; 5 days/week, twice daily totaling 20 sessions) of 
the left DLPC, followed by 2 weeks of maintenance sessions (15 Hz, 1 day/week, 
twice a day). Of the 16 participants who completed rTMS treatment, 56% had 
negative urine tests, craving scores significantly decreased as did participants 
depressive symptoms, anhedonia, and anxiety [96]. Other studies have reported 
benefits of rTMS for CUD when applied to the medial prefrontal cortex [81] and 
rTMS induced reductions in methamphetamine craving [85]. As with other rTMS 
research, study protocols vary greatly when examining rTMS for psychostimulant 
craving and addiction, and it is of note that investigators are now attempting to 
synthesize knowledge gained across studies to design and optimize a rTMS proto-
cols for treating CUD [97].
The significant degree of support for the efficacy of rTMS for SUD comes from 
research on nicotine dependence [83]. Multiple studies have reported 1–2 rTMS 
13
An Evaluation of Diverse Therapeutic Interventions for Substance Use Disorders…
DOI: http://dx.doi.org/10.5772/intechopen.98514
sessions applied to the left DLPC results in reduced craving for cigarettes [83]. 
Repeated rTMS has also consistently yielded attenuated nicotine craving though 
the persistence of the effects remains unclear. For example, a randomized sham-
controlled study administering 10 daily (10 Hz) rTMS to the left DLPC reduced 
cigarette consumption as measured by self-report and urine cotinine levels and 
cue-induced craving, though these effects dissipated with time [98]. The majority 
of studies of rTMS for SUD have focused on the efficacy of rTMS alone while some 
started to examine it in combination with other therapies. One study examined par-
ticipants randomly assigned to receive 13 daily treatments of high-frequency, low-
frequency or sham rTMS with and without cue exposure prior to treatment. Deep 
rTMS was bilaterally administered above the lateral prefrontal cortex and insula. 
High, but not low, frequency deep rTMS significantly attenuated cigarette smoking 
and when combined with smoking cues further facilitated reduction in cigarette 
use leading to an abstinence rate of 44% following the treatment and an estimated 
abstinence rate of 33% at 6 months [99]. A recent systematic review of the efficacy 
of rTMS for nicotine consumption and craving concluded that no recommendation 
beyond the possibility that HF-rTMS of the left DLPFC is effective for attenuating 
craving and consumption could be made and that while rTMS may be most effective 
when combined with other approaches, recent results obtained when combining 
approaches require replication and more rigorous evaluation [100].
Because rTMS is a neural circuit-based treatment approach rather than 
neurotransmitter focused and is directly administered to the brain, rather than 
systemically given, it is well tolerated. Adverse events are uncommon and tend to 
include transient headache and scalp discomfort. However, caution applying rTMS 
may be warranted in those with greater seizure risk such as individuals actively 
using psychostimulants or undergoing alcohol withdrawal [80]. rTMS may also 
be advantageous as it circumvents issues of medication adherence, cost, and side 
effects associated with most pharmacotherapies. The long-term efficacy of rTMS 
for decreasing drug craving in those with SUD is a potential concern given most 
studies assess these variables following relatively short-term administration periods 
(days-weeks) [81–83] or after limited follow-up periods [89]. However, one recent 
study suggests rTMS effects have the potential to be more protracted [85].
While initial rTMS results investigating craving and substance use among those 
with SUD are promising current findings still require replication in double blind 
studies with larger sample sizes [81–83]. Moreover, studies showing reduction in 
symptoms of SUD beyond craving are uncommon [82] and given long-term effects 
from rTMS are only achieved following weeks of stimulation sessions the approach 
may be time intensive and costly [86]. Several aspects of rTMS treatment are robust 
and reliable such as regional specificity, depth of magnetic field, dose dependent 
amplification of behavior, polysynaptic engagement, and frequency dependent 
effects. However, many treatment parameters are yet to be determined including 
the optimal number of daily sessions, the optimal number of total sessions, efficacy 
of rTMS for attenuating drug consumption when applied to regions other than the 
DLPFC, optimal coil orientation relative to anatomy, and an appreciation of the 
synergy between rTMS and other therapeutic approaches [80–82]. It is also worth 
highlighting that much of our understanding of addiction has moved away from 
purely drug-centered model which focuses on the neurochemical changes that 
result from drug exposure towards a more individual-centered model whereby 
individual differences in vulnerability to developing addiction are recognized. With 
this paradigm shift future application of rTMS might benefit from using individual 
MRIs and TMS navigator devices to individualize and maximize its physiological 
and therapeutic effects [82, 93].
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5. Conclusion
The process of bringing a new therapeutic approach into practice in a larger 
population is multifaceted and hinges on regulatory procedures, safety, efficacy, 
need, cost, among other variables. Moreover, this process is rarely linear as new 
research is published and the zeitgeist for various therapies changes. Where there 
remains little controversy is that while SUD treatment has seen growing suc-
cess, evidenced-based therapeutic options are still limited and not effective for 
all patients. Developing novel approaches continues to be paramount given the 
psychological, social, healthcare, and economic costs of drug addiction.
The reemergence of research on serotonergic hallucinogens, most notably 
psilocybin, is of particular significance as it appears effective and well tolerated 
for treating SUD in the limited research that has been conducted. This conclusion 
is further bolstered by research examining the efficacy of psilocybin and related 
drugs for the variety of psychological disorders that are also part of the milieu of 
addiction. The dramatic and long-lasting nature of psilocybin’s effects on meaning, 
spirituality and drug use appears to address the chronic nature of SUD in ways not 
achieved by most treatment approaches. Likewise, the potential therapeutic use of 
rTMS for SUD and other psychological disorders is notable for its efficacy, safety, 
and anti-craving effects, the latter of which is both central to addiction yet remains 
particularly challenging to resolve. The promise of these two approaches is hard 
to overstate yet in the absence of findings from larger randomized, double-blind 
clinical trials these approaches will continue to be viewed as merely promising. 
Anti-addiction vaccines, while potentially beneficial, require further technical 
refinement and appreciation of their place among therapeutic modalities.
As research on these approaches progresses it is not too early to consider how 
these therapies might be scaled to treat the large number of people affected by SUD. 
While some of these questions have begun to be addressed, such as the optimiza-
tion of treatment protocols and how to best integrate them with other treatment 
modalities, larger issues loom. Who will be trained to administer these therapies 
and where will they be administered? Overcoming the public’s negative perception 
and misunderstanding of hallucinogenic drugs, electroshock therapy, and vaccine 
hesitancy are all barriers to scaling these therapeutic approaches which are unfamil-
iar to most and therefore susceptible to misunderstanding and misinformation. The 
use of newer pharmacotherapies for SUD over the past 30 years has been slow to be 
adopted by healthcare providers partially due to their lack of awareness and com-
fort with these new approaches. The inclusion of these interventions in graduate 
education across medical, psychological, and healthcare occupations might promote 
their integration as future treatment options for those with SUD. Consideration of 
these issues today will likely ease the transition of these and other novel therapeutic 
techniques for SUD into widespread use moving forward.
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